Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vimian Group AB ( (SE:VIMIAN) ) has provided an update.
Vimian Group AB announced the release of its Interim Report for the third quarter of 2025, scheduled for October 22. The report will be presented via an audiocast by CFO and interim CEO Carl-Johan Zetterberg Boudrie and Magnus Kjellberg, CEO of the Specialty Pharma segment. This event is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction.
The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK37.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.
More about Vimian Group AB
Vimian is a global animal health company based in Stockholm, Sweden, specializing in Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. The company serves over 17,000 veterinary clinics and laboratories, operates in more than 80 markets, employs 1,200 people, and generates annual revenues of approximately EUR 375 million.
YTD Price Performance: -29.60%
Average Trading Volume: 715,564
Technical Sentiment Signal: Sell
Current Market Cap: SEK14.74B
For detailed information about VIMIAN stock, go to TipRanks’ Stock Analysis page.